Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1671
    +0.0014 (+0.12%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.14%)
     

  • Bitcoin GBP

    51,118.40
    -570.67 (-1.10%)
     

  • CMC Crypto 200

    1,331.37
    -65.17 (-4.67%)
     

  • S&P 500

    5,107.89
    +59.47 (+1.18%)
     

  • DOW

    38,281.69
    +195.89 (+0.51%)
     

  • CRUDE OIL

    83.62
    +0.05 (+0.06%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

NewLink Shares Plunge After Incyte & Merck's Study Fails

Zacks Equity Research
Updated

Shares of NewLink Genetics Corp. NLNK plunged about 43% after it announced that it conducting a review of studies evaluating its IDO pathway inhibitor, indoximod in combination with anti-PD-1/PD-L1 agents in several cancer indications including melanoma. Shares of the company have also declined 77% over a year compared with the industry’s decline of 11.5%.

 

NewLink’s decision came in response to the Incyte Corp.’s INCY  and partner Merck MRK announcement of the failure of a key melanoma combination study on Friday Incyte and Merck said that a combination of Incyte’s epacadostat and Merck’s Keutruda failed in achieving improved progression free survival over Keytruda alone in phase III study ECHO-301/KEYNOTE-252. The study was evaluating the combination drugs for the treatment unresectable or metastatic melanoma.

ADVERTISEMENT

An external data monitoring committee recommended the termination of the study following the review of the data from the pivotal study.

Data from the phase III study demonstrated that a combination of IDO1 inhibitor and PD-1 antagonists may not hold potential in treatment of melanoma which obviously raised doubts over the potential success of indoximod combination studies with anti-PD-1/PD-L1 agent.

Newlink will provide an update when the review is complete. Newlinkclaims that indoximod has a differentiated mechanism of action (MOA) and it has demonstrated that it can improve the outcomes for patients with cancer in combination studies.

The results of the ECHO-301 study also affected several companies like Bristol-Myers Squibb’s BMY which are developing combination immunotherapies for the treatment of cancer.

NewLink Genetics Corporation Price

NewLink Genetics Corporation Price | NewLink Genetics Corporation Quote

Zacks Rank

NewLink carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
Incyte Corporation (INCY) : Free Stock Analysis Report
 
NewLink Genetics Corporation (NLNK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research